Schools get federal funding to stock naloxone and train staff for overdose emergencies
S. 3588 — School Access to Naloxone Act of 2026 · Filed by Jeff Merkley (D-OR) · 6 cosponsors · Introduced Jan 7, 2026 · Hearing held
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes federal grants to schools to stock naloxone (an opioid overdose reversal drug) and train school staff to administer it in emergencies. Schools receiving grants must designate trained personnel, maintain accessible naloxone supplies, ensure trained staff are present during operating hours, and operate under state civil liability protections for staff who administer the drug.
Why we flagged it
The bill's core mechanism is a federal grant program to equip schools with naloxone and trained personnel to respond to opioid overdoses. It is a straightforward public health intervention, not a regulatory carve-out or industry subsidy.
What the text implies
- Naloxone manufacturers (Amphastar, Emergent BioSolutions, Pfizer, others) may see increased demand if schools purchase supplies, though the bill does not mandate procurement from specific vendors or guarantee purchase volumes.
- Schools must establish civil liability protections for staff before receiving grants; states lacking adequate Good Samaritan laws may need to pass new legislation, creating a compliance burden on state legislatures.
The full analysis lists 4 implications of this text.
Who stands to gain
naloxone manufacturers (Amphastar, Emergent BioSolutions, Pfizer, others); pharmaceutical distributors; school-based health center operators